4D Molecular Therapeutics, Inc. (FDMT)
收市後：
| 前收市價 | 12.31 |
| 開市 | 12.36 |
| 買盤 | 11.69 x 800 |
| 賣出價 | 12.30 x 800 |
| 今日波幅 | 12.20 - 13.08 |
| 52 週波幅 | 9.44 - 26.49 |
| 成交量 | |
| 平均成交量 | 344,174 |
| 市值 | 526.724M |
| Beta 值 (5 年，每月) | 2.45 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.65 |
| 業績公佈日 | 2023年11月09日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 33.25 |
Benzinga4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why
4D Molecular Therapeutics (NASDAQ: FDMT) announced interim data from the 4D-710 Phase 1/2 AEROW trial for cystic fibrosis lung disease. The aerosol delivery procedure for 4D-710 was well tolerated. One patient experienced mild dry throat and fatigue during aerosol delivery. Following aerosol administration, 4D-710 was well tolerated in all 3 participants (9-12 months follow-up) with no 4D-710-related adverse events, dose-limiting toxicities, or serious adverse events. Biomarker analyses demonstr
BenzingaWhat's Going On With 4D Molecular Therapeutics Stock Today
4D Molecular Therapeutics (NASDAQ: FDMT) shares are trading lower after the company released interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM trial for wet age-related macular degeneration (wet AMD). 4D Molecular Therapeutics is down on heavy volume, with a session volume of 1.54 million shares traded, compared to the trailing 100-day volume of 413.919K shares. The company said 4D-150 was well-tolerated at all three doses. All doses demonstrated clinica
InvestorPlace7 Biotech Stocks Sitting in the Sweet Spot
Biotech stocks aren’t for everyone. They require some additional research and as an investor you have to be comfortable having product pipelines with a long pathway to market. Biotech companies can pour millions into research and development and have nothing to show with it. Biotech companies are on the leading edge of scientific innovation, and they bring in massive profits if they develop a drug that’s deemed to be safe and marketable. Small biotech companies that have potentially attractive d
